Skip to main content
Premium Trial:

Request an Annual Quote

Enzo Biochem Posts Broader Revenue and Income in Q3

NEW YORK, June 17 - Enzo Biochem today reported a narrow increase in total third-quarter revenue, a broader net income, and a slight jump in R&D spending.


Total revenue for the three months ended April 30 was $15 million compared with $14 million in the same quarter one year ago, the company said. Revenues from product development and clinical lab services grew to $8.2 million from $4.8 million, and to $6.8 million from $9.1 million, year over year, respectively.


R&D spending in the quarter was $2.1 million compared with $1.7 million in the same quarter 2001. As a result, the company reported a jump in net income to $2.6 million, or $.09 per share, from $1.9 million, or $.06 per share, in the year-ago period.


Enzo Biochem, based in Farmingdale, NY, said it had around $64 million in cash and cash equivalents as of April 30.


Click here for more information.

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.